AU647070B2 - Liposome-containing intranasal vaccine formulation - Google Patents

Liposome-containing intranasal vaccine formulation

Info

Publication number
AU647070B2
AU647070B2 AU69990/91A AU6999091A AU647070B2 AU 647070 B2 AU647070 B2 AU 647070B2 AU 69990/91 A AU69990/91 A AU 69990/91A AU 6999091 A AU6999091 A AU 6999091A AU 647070 B2 AU647070 B2 AU 647070B2
Authority
AU
Australia
Prior art keywords
liposome
vaccine formulation
intranasal vaccine
containing intranasal
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU69990/91A
Other languages
English (en)
Other versions
AU6999091A (en
Inventor
Harmen Jacob Geerligs
Jan Christiaan Wilschut
Aalzen De Haan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Biologicals BV
Original Assignee
Duphar International Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar International Research BV filed Critical Duphar International Research BV
Publication of AU6999091A publication Critical patent/AU6999091A/en
Application granted granted Critical
Publication of AU647070B2 publication Critical patent/AU647070B2/en
Assigned to SOLVAY BIOLOGICALS B.V. reassignment SOLVAY BIOLOGICALS B.V. Alteration of Name(s) in Register under S187 Assignors: DUPHAR INTERNATIONAL RESEARCH B.V.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU69990/91A 1990-01-29 1991-01-25 Liposome-containing intranasal vaccine formulation Expired AU647070B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9000207 1990-01-29
NL9000207A NL9000207A (enrdf_load_stackoverflow) 1990-01-29 1990-01-29

Publications (2)

Publication Number Publication Date
AU6999091A AU6999091A (en) 1991-08-01
AU647070B2 true AU647070B2 (en) 1994-03-17

Family

ID=19856496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69990/91A Expired AU647070B2 (en) 1990-01-29 1991-01-25 Liposome-containing intranasal vaccine formulation

Country Status (15)

Country Link
US (1) US5756104A (enrdf_load_stackoverflow)
EP (1) EP0440289B1 (enrdf_load_stackoverflow)
JP (1) JP2997073B2 (enrdf_load_stackoverflow)
AT (1) ATE131723T1 (enrdf_load_stackoverflow)
AU (1) AU647070B2 (enrdf_load_stackoverflow)
CA (1) CA2035097A1 (enrdf_load_stackoverflow)
DE (1) DE69115514T2 (enrdf_load_stackoverflow)
DK (1) DK0440289T3 (enrdf_load_stackoverflow)
ES (1) ES2082107T3 (enrdf_load_stackoverflow)
GR (1) GR3019213T3 (enrdf_load_stackoverflow)
HU (1) HUT61204A (enrdf_load_stackoverflow)
IE (1) IE74950B1 (enrdf_load_stackoverflow)
IL (1) IL97014A (enrdf_load_stackoverflow)
NL (1) NL9000207A (enrdf_load_stackoverflow)
ZA (1) ZA91531B (enrdf_load_stackoverflow)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4136553A1 (de) * 1991-11-06 1993-05-13 Biotechnolog Forschung Gmbh Impfstoff gegen schleimhauterreger und herstellungsverfahren
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
EP1013269A4 (en) * 1997-06-06 2002-02-20 Shionogi & Co IMPROVEMENT OF A DRUG ADMINISTRATION SYSTEM
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
DE69901284T2 (de) * 1999-01-27 2002-11-28 Idea Ag Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
EP1280520B2 (en) * 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
CA2467833A1 (en) * 2001-11-19 2003-09-04 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
CN101107009B (zh) * 2005-01-20 2014-08-06 伊斯克诺瓦公司 包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
ES2272178B1 (es) * 2005-09-19 2008-03-16 Daniel Serrano Gil Una composicion para ser administrada a un mamifero o a un ser humano.
US20080033038A1 (en) * 2006-07-07 2008-02-07 Shytle R D Compositions of polyphenols and methods of use
DK2861214T3 (da) * 2012-06-14 2020-10-12 Univ Bern Tilpassede liposomer til behandling af bakterieinfektioner
ES2442450B1 (es) * 2012-08-09 2014-12-12 Enoc Solutions, S.L. Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional
JP2016529284A (ja) 2013-08-27 2016-09-23 ノースイースタン ユニバーシティ ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
WO1989005631A1 (fr) * 1987-12-21 1989-06-29 Institut Pasteur Compositions presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
US4323561A (en) * 1977-09-06 1982-04-06 Temple University Of The Commonwealth System Of Higher Education Process of enhancing immmunogenic response in mammals by the administration of synthetic glycolipid adjuvants
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4310550A (en) * 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
HU184141B (en) * 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4684625A (en) * 1982-07-08 1987-08-04 Syntex (U.S.A.) Inc. Method for enhancing the anti-infective activity of muramyldipeptide derivatives
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
DE3410238A1 (de) * 1984-03-21 1985-10-03 Bayer Ag, 5090 Leverkusen Glycolipid-aehnliche substanzen in liposomenform
DE3412793A1 (de) * 1984-04-05 1985-10-17 Basotherm GmbH, 7950 Biberach Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
WO1989005631A1 (fr) * 1987-12-21 1989-06-29 Institut Pasteur Compositions presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire

Also Published As

Publication number Publication date
DE69115514T2 (de) 1996-06-05
IL97014A (en) 1995-01-24
ATE131723T1 (de) 1996-01-15
GR3019213T3 (en) 1996-06-30
EP0440289B1 (en) 1995-12-20
HUT61204A (en) 1992-12-28
JP2997073B2 (ja) 2000-01-11
CA2035097A1 (en) 1991-07-30
HU910256D0 (en) 1991-08-28
IL97014A0 (en) 1992-03-29
DK0440289T3 (da) 1996-03-04
NL9000207A (enrdf_load_stackoverflow) 1991-08-16
IE910268A1 (en) 1991-07-31
AU6999091A (en) 1991-08-01
IE74950B1 (en) 1997-08-13
JPH04210925A (ja) 1992-08-03
DE69115514D1 (de) 1996-02-01
EP0440289A1 (en) 1991-08-07
ZA91531B (en) 1991-10-30
US5756104A (en) 1998-05-26
ES2082107T3 (es) 1996-03-16

Similar Documents

Publication Publication Date Title
AU647070B2 (en) Liposome-containing intranasal vaccine formulation
IL112618A (en) Insulin composition and a method for the preparation thereof
EP0619742A4 (en) Transfection of lung via aerosolized transgene delivery.
GR3025184T3 (en) Vaccine composition containing adjuvants.
ZA914957B (en) Aerosol drug formulations
GB8921222D0 (en) Medicinal aerosol formulations
EP0372777A3 (en) Medicinal aerosol formulations
EP0734710A3 (en) Medicament and support
AU3152993A (en) Improvements in the administration of aerosol compounds
AU7472191A (en) Therapeutic composition containing a phenol compound and propolis useful against lipidic capside viruses, especially the herpes viruses
EP0437729A3 (en) New peptides, procedure for their preparation and their use as a medicament, especially their use as medicament against retroviruses
PH30098A (en) 4,13-dioxabicyclo¬8.2.1¾ tridecenone compounds and pharmaceutical compositions containing them
EP0218679A4 (en) AEROSOL AGENT FOR NOSE SPRAYING OF VITAMIN B 12.
AU8251591A (en) Novel pyrrolobenzimidazoles, imidazobenzoxazinones and imidazoquinolones, process for their preparation and their use and preparations containing the compounds
DE59203456D1 (de) Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung.
ZA934971B (en) Novel phospholipid derivatives
GB8911259D0 (en) Inhalation medicament
GR880300141T1 (en) Bacterial antigenic lysate, a process for the preparation thereof and pharmaceutical compositions containing it
EP0505608A3 (en) Alpha-dihydroergocryptine pharmaceutical preparations with neuroprotective acitivity
LTIP461A (en) Non-stinging vaccine composition
GB9006450D0 (en) Inhalation formulation
GB9106243D0 (en) Inhalation formulation
HK1004200A (en) Aerosol drug formulations
GB8920348D0 (en) Medicinal aerosol formulations